Physician profile
Lourdes Bosch
NPI 1053394247
$6,865.62
in general payments reported to CMS, 2019-2025
25 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $156 · 2021: $270 · 2022: $4,153 · 2023: $1,736 · 2024: $233 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,376 · Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,376.21 |
| Food and Beverage | $740.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,719.83 | 2022 | |
| Chiesi USA, INC. | $1,376.21 | 2023 | |
| Glaxosmithkline, LLC. | $576.68 | 2019-2024 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $404.71 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.97 | 2019-2025 | Ofev |
| Exact Sciences Corporation | $89.95 | 2023 | Cologuard Collection Kit |
| Philips North America LLC | $74.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $58.81 | 2021 | |
| Insmed, INC. | $53.14 | 2019-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $50.44 | 2022 | |
| Lilly USA, LLC | $46.21 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.58 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.04 | 2022 | |
| Mallinckrodt Hospital Products INC. | $34.14 | 2024 | Acthar |
| Genzyme Corporation | $27.02 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $20.07 | 2019 | |
| Amgen INC. | $18.64 | 2025 | Repatha |
| Mylan Specialty L.P. | $15.05 | 2020 | |
| Novo Nordisk INC | $14.69 | 2023 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lourdes Bosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.